Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Current Leases (2019 - 2025)

Voyager Therapeutics' Current Leases history spans 7 years, with the latest figure at $7.8 million for Q4 2025.

  • For Q4 2025, Current Leases rose 8.48% year-over-year to $7.8 million; the TTM value through Dec 2025 reached $7.8 million, up 8.48%, while the annual FY2025 figure was $7.8 million, 8.48% up from the prior year.
  • Current Leases for Q4 2025 was $7.8 million at Voyager Therapeutics, roughly flat from $7.8 million in the prior quarter.
  • Across five years, Current Leases topped out at $7.8 million in Q3 2025 and bottomed at $2.5 million in Q2 2022.
  • The 5-year median for Current Leases is $5.4 million (2021), against an average of $5.2 million.
  • The largest annual shift saw Current Leases plummeted 49.17% in 2022 before it skyrocketed 125.84% in 2024.
  • A 5-year view of Current Leases shows it stood at $5.6 million in 2021, then tumbled by 49.17% to $2.8 million in 2022, then grew by 12.99% to $3.2 million in 2023, then surged by 125.84% to $7.2 million in 2024, then grew by 8.48% to $7.8 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Current Leases are $7.8 million (Q4 2025), $7.8 million (Q3 2025), and $7.6 million (Q2 2025).